JP2002371059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002371059A5 JP2002371059A5 JP2001145691A JP2001145691A JP2002371059A5 JP 2002371059 A5 JP2002371059 A5 JP 2002371059A5 JP 2001145691 A JP2001145691 A JP 2001145691A JP 2001145691 A JP2001145691 A JP 2001145691A JP 2002371059 A5 JP2002371059 A5 JP 2002371059A5
- Authority
- JP
- Japan
- Prior art keywords
- substituent
- ring
- compound according
- group
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001424 substituent group Chemical group 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 26
- 150000003839 salts Chemical class 0.000 description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 125000006850 spacer group Chemical group 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 5
- 150000001555 benzenes Chemical group 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 3
- 102000047659 melanin-concentrating hormone Human genes 0.000 description 3
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003667 hormone antagonist Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 1
- SPCXCXWTBGVFJF-UHFFFAOYSA-N 4,5-dihydro-3h-azepine Chemical compound C1CC=CN=CC1 SPCXCXWTBGVFJF-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 0 CCCCC(C=C1)=C(CCCCC*C)C=C*1[N+](C)[O-] Chemical compound CCCCC(C=C1)=C(CCCCC*C)C=C*1[N+](C)[O-] 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001887 anti-feedant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- -1 biphenylyl Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001145691A JP2002371059A (ja) | 2000-05-16 | 2001-05-15 | メラニン凝集ホルモン拮抗剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000148647 | 2000-05-16 | ||
| JP2000-148647 | 2000-05-16 | ||
| JP2001116219 | 2001-04-13 | ||
| JP2001-116219 | 2001-04-13 | ||
| JP2001145691A JP2002371059A (ja) | 2000-05-16 | 2001-05-15 | メラニン凝集ホルモン拮抗剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002371059A JP2002371059A (ja) | 2002-12-26 |
| JP2002371059A5 true JP2002371059A5 (enExample) | 2008-06-26 |
Family
ID=27343435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001145691A Withdrawn JP2002371059A (ja) | 2000-05-16 | 2001-05-15 | メラニン凝集ホルモン拮抗剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002371059A (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002352878B2 (en) | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
| PT1572215E (pt) * | 2002-12-20 | 2009-12-09 | Glaxo Group Ltd | Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| AU2004209505B2 (en) | 2003-02-10 | 2009-07-23 | Banyu Pharmaceutical Co., Ltd. | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| WO2005016928A1 (ja) * | 2003-08-15 | 2005-02-24 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン誘導体 |
| ATE446962T1 (de) * | 2004-12-17 | 2009-11-15 | Lilly Co Eli | Thiazolopyridinon-derivate als mch- rezeptorantagonisten |
| GB0504314D0 (en) * | 2005-03-02 | 2005-04-06 | Glaxo Group Ltd | Novel polymorph |
| US8420631B2 (en) * | 2005-09-01 | 2013-04-16 | Eli Lilly And Company | 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists |
| WO2007028132A2 (en) * | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS |
| WO2009132136A1 (en) * | 2008-04-23 | 2009-10-29 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
| ES2350077B1 (es) * | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| AU2012308243B2 (en) * | 2011-09-15 | 2017-09-14 | Taipei Medical University | Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury |
-
2001
- 2001-05-15 JP JP2001145691A patent/JP2002371059A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2462995T3 (es) | Derivados de 2-iminoisoindolinona como antagonistas del receptor de la trombina | |
| JP2011527334A5 (enExample) | ||
| JP2008538574A5 (enExample) | ||
| JP2006527776A5 (enExample) | ||
| JP2009534468A5 (enExample) | ||
| CA2407149A1 (en) | Melanin-concentrating hormone antagonist | |
| JP2010155827A5 (enExample) | ||
| JP2006500370A5 (enExample) | ||
| CA2686545A1 (en) | Deuterated morpholinyl compounds | |
| JP2006507355A5 (enExample) | ||
| JP2005527542A5 (enExample) | ||
| JP2006523193A5 (enExample) | ||
| JP2011511075A5 (enExample) | ||
| JP2007246474A5 (enExample) | ||
| JP2006522141A5 (enExample) | ||
| JP2004532240A5 (enExample) | ||
| JP2005511594A5 (enExample) | ||
| JP2006523192A5 (enExample) | ||
| JP2007538031A5 (enExample) | ||
| JP2005533052A5 (enExample) | ||
| JP2009501745A5 (enExample) | ||
| JP2005508969A5 (enExample) | ||
| JP2006513232A5 (enExample) | ||
| JP2005527521A5 (enExample) | ||
| JP2001522836A5 (enExample) |